Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
corticosteroids + montelukast
- Development stage
- Unknown
- Lead developer
- Karolinska Institutet
- Modality
- Small Molecules
- Administration
- Oral, Inhalation
01
Overview
Single corticosteroid inhalers + montelukast (also referred to as Single corticosteroid inhalers and Singulair) is a combination anti-inflammatory treatment regimen evaluated in the NOAK trial (NCT00421018) for the management of allergic asthma in adults. This regimen is not a single fixed-dose combination product but rather a treatment algorithm that combines inhaled corticosteroids (ICS) with montelukast, a leukotriene receptor antagonist (LTRA). Montelukast acts as a selective antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), blocking the bronchoconstrictor and pro-inflammatory effects of leukotriene D4 (LTD4). Inhaled corticosteroids provide broad anti-inflammatory action by binding to glucocorticoid receptors in the airways. Within the trial context, this combination was used in a step-wise approach guided either by fractional exhaled nitric oxide (FeNO) measurements or conventional symptom-based assessments to optimize asthma-related quality of life.
- Brand names
- Singulair
- Other names
- Single corticosteroid inhalers + montelukastSingle corticosteroid inhalers and SingulairICS + montelukast
02
Targets
GR (Glucocorticoid receptor)CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)MR (Mineralocorticoid receptor)CYSLTR2 (Cysteinyl leukotriene receptor 2)
Beyond the preview
Go deeper on corticosteroids + montelukast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on corticosteroids + montelukast.